201 related articles for article (PubMed ID: 34385243)
1. Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy.
Wilson M; Thavorn K; Hawrysh T; Graham ID; Atkins H; Kekre N; Coyle D; Lalu MM; Fergusson DA; Chan KK; Ollendorf DA; Presseau J
BMJ Open; 2021 Aug; 11(8):e046707. PubMed ID: 34385243
[TBL] [Abstract][Full Text] [Related]
2. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
3. Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study).
Hughes SE; McMullan C; Aiyegbusi OL; Shaw K; Kinsella F; Ferguson P; Khatsuria F; Burns D; Pyatt L; Ansell J; Chakera E; Richardson-Abraham J; Denniston AK; Davies EH; Craddock C; Calvert M
BMJ Open; 2024 Mar; 14(3):e085392. PubMed ID: 38553074
[TBL] [Abstract][Full Text] [Related]
4. Patient-Oriented Research Competencies in Health (PORCH) for patients, healthcare providers, decision-makers and researchers: protocol of a scoping review.
Mallidou AA; Frisch N; Doyle-Waters MM; MacLeod MLP; Ward J; Atherton P
Syst Rev; 2018 Jul; 7(1):101. PubMed ID: 30025543
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
6. PROTOCOL: Barriers and facilitators to stakeholder engagement in health guideline development: A qualitative evidence synthesis.
Magwood O; Riddle A; Petkovic J; Lytvyn L; Khabsa J; Atwere P; Akl EA; Campbell P; Welch V; Smith M; Mustafa RA; Limburg H; Dans LF; Skoetz N; Grant S; Concannon T; Tugwell P
Campbell Syst Rev; 2022 Jun; 18(2):e1237. PubMed ID: 36911345
[TBL] [Abstract][Full Text] [Related]
7. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
10. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
11. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
12. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
13. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy.
Gye A; Lourenco RA; Goodall S
Value Health; 2024 Apr; 27(4):415-424. PubMed ID: 38301961
[TBL] [Abstract][Full Text] [Related]
14. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
15. Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience.
Wilson M; Thavorn K; Hawrysh T; Graham ID; Atkins H; Kekre N; Coyle D; Lalu MM; Fergusson DA; Chan KKW; Ollendorf DA; Presseau J
Pharmacoeconomics; 2022 Nov; 40(11):1119-1130. PubMed ID: 36071263
[TBL] [Abstract][Full Text] [Related]
16. Stakeholder Engagement in Planning the Design of a National Needs Assessment for Cardiovascular Disease Prevention and Management in Nepal.
Archana S; Karmacharya BM; Rashmi M; Abhinav V; Meghnath D; Natalia O; Rajeev S; Prajjwal P; Annette F; David C; Swornim B; Roman XD; Donna S; Rajendra K
Glob Heart; 2019 Jun; 14(2):181-189. PubMed ID: 31324373
[TBL] [Abstract][Full Text] [Related]
17. Stakeholders' engagement in co-producing policy-relevant knowledge to facilitate employment for persons with developmental disabilities.
Khayatzadeh-Mahani A; Wittevrongel K; Petermann L; Graham ID; Zwicker JD
Health Res Policy Syst; 2020 Apr; 18(1):39. PubMed ID: 32303228
[TBL] [Abstract][Full Text] [Related]
18. Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Lalu MM; Kekre N; Montroy J; Ghiasi M; Hay K; McComb S; Weeratna R; Atkins H; Hutton B; Yahya A; Masurekar A; Sobh M; Fergusson DA
Syst Rev; 2023 Jan; 12(1):9. PubMed ID: 36653879
[TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
20. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W;
Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
